I know what you mean Buckeyes, I'm sure we've all felt those feelings of "this will help" only to see whatever it is go nowhere. To me it boils down to continued weakness at the top has always left the company in dire financial straits and unable to sustain itself when trials haven't run to perfection.  It's not hard for the market to see this destructive pattern and consequently has no trust in management.

It is an absolute disgrace that a phase 3 company with this much potential opportunity has been so let down by management that it's market cap is less than many pre-clinical biotechs.  Don can blame general market conditions all he wants but to me that is clearly not the problem. 

I would feel a lot better about this if this company was in more competent, experienced hands. Apparently the market agrees.  Hopefully one of these attempts at a deal works out and the science does seem so close. I guess we will see.